

**Amendments to the Specification:**

On page 35, line 1, of the originally filed specification, please replace "ABSTRACT OF THE INVENTION" with:

- - ABSTRACT - -

Please replace the paragraph appearing on page 27, l. 4-10 of the originally filed specification (paragraph no. [0094] in corresponding U.S. Pub. No. 2002/0160003) with the following amended paragraph:

The murine epitope sequence recognized by antibody E4B9 (peptide 1) shares 100% homology with human VE-cadherin, so this antibody was examined to determine if it cross-reacts with human VE-cadherin. Western-blot analysis of several VE-cadherin expressing human and murine cell indicated that E4B9 indeed cross-reacts with human VE-cadherin (FIG. 6). This finding facilitates development of a "humanized" E4B9 antibody and its success in the preclinical development since its anti-tumor activity can be tested extensively in several mouse models.